Search Press releases Keywords From To 5 Aug 2024 UCB announces European Commission approval for 320 mg device presentations of BIMZELX[®]▼(bimekizumab) Read More 25 Jul 2024 Strong Start into UCB’s Decade of Growth Read More 28 Jun 2024 Acquisition of own shares Read More 28 Jun 2024 UCB spotlights new analyses and patient insights supporting its recently launched gMG portfolio at the 10th Congress of the European Academy of Neurology (EAN) Read More 26 Jun 2024 UCB’s epilepsy drug BRIVIACT[®](brivaracetam)[1] approved in Japan for treatment of focal onset seizures Read More 14 Jun 2024 Acquisition of own shares Read More Pagination First page Previous page Previous … Page 4 Page 5 Page 6 Page 7 Current page 8 Page 9 Page 10 Page 11 Page 12 … Page 8 of 74 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe